Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background PD1 antagonists are on the forefront of HIV curative strategies, but systemic treatment doses have led to limiting autoimmune toxicities. As such, there is interest in using subcutaneous low-dose delivery, but data are lacking. We recently completed a trial to evaluate low dose (10 mg or ~1.4 mg/kg) intra-lesional nivolumab in 6 males with…
Background Long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) has changed the landscape of antiretroviral therapy (ART) by creating an alternative to daily oral ART. While FDA approval is currently limited to individuals with viral load suppression (VLS), there is growing evidence that CAB/RPV may also benefit virally unsuppressed patients who face adherence challenges taking oral ART. Our study…
Background Real world data continues to accumulate regarding the efficacy of long acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV); however, limited data exists regarding virologic outcomes in those returning to oral therapy after discontinuing LAI CAB/RPV. Methods Single-center cohort study at the UC San Diego Owen Clinic in those who initiated LAI CAB/RPV but discontinued treatment between…
Background Long-acting Cabotegravir and Rilpivirine (LA-CAB/RPV), approved in January 2021, is the first complete injectable regimen for virologically suppressed patients with HIV-1 without a history of resistance. The availability of LA-CAB/RPV offers a significant opportunity to expand the landscape of care for people with HIV. However, data on its implementation outside of early phase clinical…
Background Various distance to care (DTC) measures exist. It is unclear which most accurately predicts injection visit adherence for persons with HIV receiving long acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV). Objectives were to: i) identify which DTC measures were associated with injection visit no-shows (IVNS) and ii) compare the strength of association of each DTC measure…
Background The Ward 86 HIV Clinic in San Francisco serves publicly-insured people with HIV (PWH) living with multiple concomitant challenges. With the approval of long-acting (LA) cabotegravir/rilpivirine in 2021, Ward 86 started using LA antiretroviral therapy (ART) for those with adherence challenges to oral ART. More than 3.5 years into the program, we now report…
Background HIV-1 replicates in different body compartments and sub-compartments characterized by distinct compositions of small solutes and proteins. It is often assumed that virus proteins maintain the same conformation, function and sensitivity to inhibitors in different molecular environments, in vivo and in vitro. The protein albumin shows remarkable variability in concentration between the blood and…
Background In Vietnam, including Haiphong, many hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In 2016, there were an estimated 10,000 people with a history of injecting drug use (IDU) in Haiphong. Multiple respondent-driven sampling (RDS) surveys tested for HCV among PWID in Haiphong, and a survey intervention (ANRS 12380 DRIVE-C)…
Background This study aimed to investigate prevalence of lean metabolic associated fatty liver disease (lean MAFLD) in people living with HIV(PLWH) and the value of ten diagnostic models in MAFLD among PLWH. Methods Transient Elastography (Fibroscan), Controlled attenuation parameter (CAP) and ultrasonography were performed among PLWH. MAFLD was defined by the 2024 revised edition of the…
Background Hepatic steatosis is an increasingly important comorbidity in aging people with HIV (PWH). Population-representative estimates of incidence, risk factors and association with liver-related events are not well understood. We evaluated the incidence of hepatic steatosis and its association with liver-related events and overall mortality within the NA-ACCORD. Methods Hepatic steatosis was defined using the…